PROFESSIONAL INFORMATION LEAFLET: OLOPAGEN™ ONCE DAILY OPHTHALMIC SOLUTION

SCHEDULING STATUS **S2**

1. NAME OF THE MEDICINE

OLOPAGEN ONCE DAILY 2 mg/ml ophthalmic solution

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains 2,22 mg of olopatadine hydrochloride equivalent to 2 mg/ml olopatadine.

Preservative: Benzalkonium chloride 0,01 % *m/v*.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Sterile ophthalmic solution.

Colourless to slightly yellowish solution, without suspending particles.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

OLOPAGEN ONCE DAILY is indicated for the temporary prevention and treatment of itching of the eye associated with allergic conjunctivitis.

4.2 Posology and method of administration

Posology:

Instil one drop of OLOPAGEN ONCE DAILY in the conjunctival sac of the affected eye(s) once daily.

Special populations:

Use in elderly:

No dosage alteration in elderly patients is necessary.

Paediatric population:

OLOPAGEN ONCE DAILY may be used in paediatric patients (3 years of age and older) at the same posology as in adults. The safety and efficacy of OLOPAGEN ONCE DAILY in children aged under 3 years has not been established. No data are available.

Use in renal impairment:
OLOPAGEN ONCE DAILY has not been studied in patients with renal disease. However, no dosage adjustment is expected to be necessary in renal impairment (see section 5.2).

Use in hepatic impairment:
Hepatic metabolism represents a small fraction of olopatadine elimination. Therefore, hepatic impairment is not expected to alter the pharmacokinetics of olopatadine and no dose adjustment is necessary.

Method of administration:
For ocular use only.
To prevent contamination of the dropper tip and solution, care must be taken not to touch the eyelids, surrounding areas or other surfaces with the dropper tip of the bottle. Keep the bottle tightly closed when not in use.
In case of concomitant therapy with other topical ocular medicines, an interval of five minutes should be allowed between successive applications. Eye ointments should be administered last.

4.3 Contraindications

- Hypersensitivity to olopatadine hydrochloride or to any of the excipients of OLOPAGEN ONCE DAILY listed in section 6.1.

4.4 Special warnings and precautions for use

OLOPAGEN ONCE DAILY contains benzalkonium chloride as a preservative, which may be absorbed by soft contact lenses. Contact lenses should be removed prior to administration of OLOPAGEN ONCE DAILY and may be reinserted 10 minutes following administration. Do not administer OLOPAGEN ONCE DAILY while wearing contact lenses.

Benzalkonium chloride, has also been reported to cause punctate keratopathy and/or toxic ulcerative keratopathy.
As the possibility of adverse effects on the corneal permeability, and the danger of disruption of the corneal epithelium with prolonged or repeated usage of benzalkonium chloride preserved ophthalmological preparations, cannot be excluded, regular ophthalmological examination is required.

Caution should be exercised in the use of benzalkonium chloride preserved topical medicine over an extended period in patients with extensive ocular surface disease.

4.5 Interaction with other medicines and other forms of interaction

In case of concomitant therapy with other topical ocular medicines, an interval of 5 minutes should be allowed between successive applications.

No human clinical interaction studies with other medicines were performed with OLOPAGEN ONCE DAILY.

Experimental studies have shown that olopatadine did not inhibit metabolic reactions, which involve cytochrome P-450 isozymes.

No significant interaction was noted following systemic administration of olopatadine and the CYP3A4 inhibitor itraconazole in studies evaluating pro-arrhythmic potential. These results indicate that olopatadine is unlikely to result in metabolic interactions with other concomitantly administered active substances.

4.6 Fertility, pregnancy and lactation

Pregnancy:

No adequate and well-controlled studies were performed in pregnant women. Studies in animals have shown reproductive toxicity at systemic doses well in excess of the maximal level recommended for human ocular use. Because animal studies are not always predictive of human responses, the use of OLOPAGEN ONCE DAILY in pregnancy is not recommended.

Breastfeeding:

It is not known whether topical administration to humans could result in sufficient systemic absorption to produce detectable quantities in human breast milk. OLOPAGEN ONCE DAILY is not recommended for breastfeeding mothers.

Fertility:

Studies have not been performed to evaluate the effect of topical ocular administration of olopatadine on human fertility.

4.7 Effects on ability to drive and use machines

Temporary blurred vision or other visual disturbances may affect the ability to drive or use machines. If blurred vision occurs at instillation, the patient must wait until the vision clears before driving or using machinery.

4.8 Undesirable effects

Summary of safety profile

In clinical trials involving 1137 patients dosed with long term ophthalmic topical therapy, olopatadine as contained in OLOPAGEN ONCE DAILY, was administered once daily for 4 to 12 weeks. The most frequently reported treatment-related undesirable effects were headache (0,8 %), eye irritation (0,5 %), dry eye (0,4 %), and eyelid margin crusting (0,4 %). No serious adverse drug reactions related to olopatadine as contained in OLOPAGEN ONCE DAILY, were reported in the clinical trials.

Table 1: Tabulated summary of adverse reactions:

The following adverse reactions have been reported during clinical studies and are classified according to the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1000) very rare (<1/10,000) or not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

System Organ Class	OLOPAGEN ONCE DAILY Side Effects
Nervous system disorders:	
Common:	Headache, dysgeusia.
Eye disorders:	
Common:	Eye irritation, eye swelling, dry eye, vision blurred, eye pruritus, eyelid pruritus, ocular hyperaemia, asthenopia, eyelid disorder, eyelid margin crusting.
Cardiac disorders:	
Common:	Heart rate increased.
Respiratory, thoracic and mediastinal disorders:	
Common:	Nasal dryness.
Gastrointestinal disorders:	
Common:	Dry mouth.

Table 2: Tabulated summary of adverse reactions (post-marketing):

No post-market reports of serious adverse reactions have been received to date. There were no new major findings bearing on the established overall safety profile of olopatadine as contained in OLOPAGEN ONCE DAILY. The most frequent events reported were eye irritation, ocular hyperaemia, eye pain and vision blurred.

System Organ Class	OLOPAGEN ONCE DAILY Side Effects
Immune system disorders:	
Frequency not known:	Hypersensitivity.
Nervous system disorders:	
Frequency not known:	Dizziness.
Eye disorders:	
Common:	Eye irritation, eye pain, vision blurred, ocular hyperaemia.
Frequency not known:	Punctate keratitis, keratitis, eye discharge, ocular discomfort, lacrimation increased, erythema of the eyelid.
Gastrointestinal disorders:	
Frequency not known:	Nausea.
Skin and subcutaneous tissue disorders:	
Frequency not known:	Dermatitis contact.
General disorders and administration site conditions:	
Frequency not known:	Fatigue.

Reporting of suspected adverse reactions

Reporting of suspected adverse reactions after authorisation of OLOPAGEN ONCE DAILY is important. It allows continued monitoring of the benefit/risk balance of OLOPAGEN ONCE DAILY. Healthcare professionals are asked to report any suspected adverse reactions. Suspected adverse reactions can be reported to Gen-Eye (Pty) Ltd via email: pharmacovigilance@gen-eye.co.za or telephonically on 011 312 3812. Suspected adverse reactions can also be reported to SAHPRA via the "6.04 Adverse Drug Reaction Reporting Form", found online under SAHPRA's publications: https://www.sahpra.org.za/Publications/Index/8.

4.9 Overdose

In overdose, side effects can be precipitated and/or be of increased severity (see section 4.8).

If overdose with OLOPAGEN ONCE DAILY occurs, treatment should be symptomatic and supportive.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacological classification: A.15.4 Ophthalmic preparations, other

Olopatadine is a selective and topically active anti-histaminic and mast-cell stabilising active ingredient.

Olopatadine prevents histamine-induced inflammatory cytokine production by human conjunctival epithelial cells.

5.2 Pharmacokinetic properties

Systemic absorption of topically applied olopatadine is minimal and generally below the limit of quantitation of the assay (<0,5 ng/ml).

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Disodium phosphate anhydrous
Monosodium phosphate dihydrate
Sodium chloride
Disodium edetate dihydrate
Benzalkonium chloride (preservative)
Purified water

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

Unopened: 2 years
After first opening: 28 days

6.4 Special precautions for storage

Store at or below 30 °C.

Keep the container well-closed and in the outer carton.

Protect from light.

Discard 28 days after first opening.

6.5 Nature and contents of container

Opaque white sterile 5 ml dropper bottle, with a white sterile capillary plug, and a white sterile cap, containing 3 ml solution.

The dropper bottle is contained in an outer cardboard carton.

6.6 Special precautions for disposal

No special requirements.

7. HOLDER OF CERTIFICATE OF REGISTRATION

Gen-Eye (Pty) Ltd[1]
Royal Palm Business Estate
Unit 7, 646 Washington Street
Halfway House, Midrand, 1685
Gauteng, South Africa

8. REGISTRATION NUMBER

47/15.4/1224

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

08 December 2022

10. DATE OF REVISION OF THE TEXT

Not applicable

[1] Company Registration Number.: 2009/009360/07

™ OLOPAGEN is a trademark of Gen-Eye (Pty) Ltd

OLOP2/PI/01/10.2022